Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

April 30, 2011

Conditions
Adenocarcinoma of Colon Recurrent
Interventions
DIETARY_SUPPLEMENT

Eviendep (CM&D Pharma Limited, UK)

175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.

DIETARY_SUPPLEMENT

Maltodextrins

900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet

Trial Locations (1)

70124

Ospedale Policlinico Consorziale - Gastroenterology Unit, Bari

Sponsors
All Listed Sponsors
lead

CM&D Pharma Limited

INDUSTRY

NCT01402648 - Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence | Biotech Hunter | Biotech Hunter